13-Aug-2026 - The Globe and Mail Can Keytruda Sustain Merck's Growth in the Second Half of 2026? Merck’s MRK strong foothold in the oncology space is backed by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounts for more than 55% of the company’s total ...
11-Aug-2026 - Yahoo Finance Merck (MRK) Wins FDA And EMA Review For Broader RSV Use In Children Merck (NYSE:MRK) said the FDA and EMA have accepted supplemental applications to expand ENFLONSIA for preventing RSV in young children at elevated risk. The filings seek to broaden ENFLONSIA's ...
13-Aug-2026 - The Globe and Mail Can Keytruda Sustain Merck's Growth in the Second Half of 2026? Merck’s MRK strong foothold in the oncology space is backed by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounts for more than 55% of the company’s total ...
11-Aug-2026 - Yahoo Finance Merck (MRK) Wins FDA And EMA Review For Broader RSV Use In Children Merck (NYSE:MRK) said the FDA and EMA have accepted supplemental applications to expand ENFLONSIA for preventing RSV in young children at elevated risk. The filings seek to broaden ENFLONSIA's ...
